Paula Ragan Biography and Net Worth

CEO of X4 Pharmaceuticals

Dr. Ragan has been X4’s President and Chief Executive Officer and a member of the X4 Board of Directors since July 2014. She has more than 18 years of experience building companies in the biotechnology industry. Prior to founding X4, Dr. Ragan consulted as Chief Business Officer at Lysosomal Therapeutics Inc., a private biopharmaceutical company, where she led the company’s business development activities. Prior to that, Dr. Ragan held leadership roles in corporate development and operations at Genzyme Corporation, a Sanofi company, where she led strategic partnering efforts for Genzyme’s Rare Disease business and headed the supply chain planning for Genzyme’s flagship commercial products. Other professional roles include business roles at Hydra Biosciences, Oscient Corporation and Celera Corporation. Dr. Ragan received her B.S. from Tufts University and her Ph.D. from Massachusetts Institute of Technology and completed post-doctoral studies at Harvard Medical School.

What is Paula Ragan's net worth?: The estimated net worth of Paula Ragan is at least $349,187.77 as of October 15th, 2024. Dr. Ragan owns 1,025,816 shares of X4 Pharmaceuticals stock worth more than $349,188 as of November 21st. This net worth estimate does not reflect any other assets that Dr. Ragan may own. Additionally, Dr. Ragan receives an annual salary of $1,010,000.00 as CEO at X4 Pharmaceuticals. Learn More about Paula Ragan's net worth.
How old is Paula Ragan?: Dr. Ragan is currently 54 years old. There are 8 older executives and no younger executives at X4 Pharmaceuticals. Learn More on Paula Ragan's age.
What is Paula Ragan's salary?: As the CEO of X4 Pharmaceuticals, Inc., Dr. Ragan earns $1,010,000.00 per year. Learn More on Paula Ragan's salary.
How do I contact Paula Ragan?: The corporate mailing address for Dr. Ragan and other X4 Pharmaceuticals executives is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. X4 Pharmaceuticals can also be reached via phone at (857) 529-8300 and via email at [email protected]. Learn More on Paula Ragan's contact information.
Has Paula Ragan been buying or selling shares of X4 Pharmaceuticals?: During the last quarter, Paula Ragan has sold $149,552.12 in shares of X4 Pharmaceuticals stock. Most recently, Paula Ragan sold 31,897 shares of the business's stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $0.56, for a transaction totalling $17,862.32. Following the completion of the sale, the chief executive officer now directly owns 1,025,816 shares of the company's stock, valued at $574,456.96. Learn More on Paula Ragan's trading history.
Who are X4 Pharmaceuticals' active insiders?: X4 Pharmaceuticals' insider roster includes Derek Meisner (General Counsel), Adam Mostafa (CFO), and Paula Ragan (CEO). Learn More on X4 Pharmaceuticals' active insiders.
Are insiders buying or selling shares of X4 Pharmaceuticals?: During the last twelve months, insiders at the sold shares 13 times. They sold a total of 766,508 shares worth more than $491,874.90. The most recent insider tranaction occured on October, 15th when CEO Paula Ragan sold 31,897 shares worth more than $17,862.32. Insiders at X4 Pharmaceuticals own 1.6% of the company. Learn More about insider trades at X4 Pharmaceuticals.
Information on this page was last updated on 10/15/2024.

Paula Ragan Insider Trading History at X4 Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/15/2024	Sell	31,897	$0.56	$17,862.32	1,025,816
10/7/2024	Sell	239,436	$0.55	$131,689.80	1,057,713
3/11/2024	Sell	49,678	$0.88	$43,716.64	765,068
2/12/2024	Sell	21,695	$1.01	$21,911.95	814,746
11/3/2023	Sell	39,906	$0.90	$35,915.40	836,441
11/1/2023	Sell	199,531	$0.73	$145,657.63	876,347
6/23/2023	Sell	6,724	$1.92	$12,910.08	543,797
6/15/2023	Sell	6,724	$2.23	$14,994.52	550,521
5/31/2023	Sell	6,292	$1.95	$12,269.40	557,245
2/13/2023	Sell	21,695	$0.93	$20,176.35	613,215
6/3/2022	Sell	6,292	$1.21	$7,613.32	661,806
8/17/2021	Sell	13,448	$5.10	$68,584.80
7/15/2021	Sell	13,448	$5.78	$77,729.44
6/2/2021	Sell	2,400	$9.50	$22,800.00
4/5/2021	Sell	2,400	$9.17	$22,008.00
3/2/2021	Sell	2,400	$9.74	$23,376.00
2/2/2021	Sell	2,400	$7.88	$18,912.00
1/5/2021	Sell	2,400	$7.00	$16,800.00	277,723
12/23/2020	Sell	4,800	$7.00	$33,600.00
10/5/2020	Sell	1,797	$7.00	$12,579.00	284,923
10/2/2020	Sell	603	$7.00	$4,221.00
9/9/2020	Sell	8,840	$8.04	$71,073.60
9/2/2020	Sell	2,400	$7.99	$19,176.00
8/3/2020	Sell	2,400	$7.45	$17,880.00
7/2/2020	Sell	2,400	$9.05	$21,720.00
6/3/2020	Sell	9,707	$8.88	$86,198.16
6/1/2020	Sell	4,275	$8.63	$36,893.25
5/4/2020	Sell	2,400	$8.92	$21,408.00
4/2/2020	Sell	2,400	$8.40	$20,160.00

Paula Ragan Buying and Selling Activity at X4 Pharmaceuticals

X4 Pharmaceuticals Company Overview

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

Today's Range

Now: $0.34

$0.31

$0.36

50 Day Range

MA: $0.57

$0.28

$0.72

2 Week Range

Now: $0.34

$0.26

$1.60

Volume

3,220,296 shs

Average Volume

2,369,976 shs

Market Capitalization

$58.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Top "Sleeping Giant" Crypto In The Market Now

From Crypto 101 Media | Ad

Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.

Click here to discover our #1 crypto pick before it's too late

Paula Ragan Biography and Net Worth

What is Paula Ragan's net worth?

How old is Paula Ragan?

What is Paula Ragan's salary?

How do I contact Paula Ragan?

Has Paula Ragan been buying or selling shares of X4 Pharmaceuticals?

Who are X4 Pharmaceuticals' active insiders?

Are insiders buying or selling shares of X4 Pharmaceuticals?